Company news

Imugene Ltd news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Next cohort reached in IV arms of CF33-hNIS (VAXINIA) study

November 1, 2023

Imugene Phase 1 onCARlytics CD19 virus clinical trial opens

October 25, 2023

Imugene B Cell & OV Platforms Featured at ESMO Congress

October 23, 2023

Azer-cel FDA IND Transferred to Imugene

September 27, 2023

Imugene Closes SPP Raising $18.2 million

September 24, 2023

Imugene PD1-Vaxx Update

September 11, 2023

Imugene Receives Positive Feedback From FDA

September 10, 2023

VAXINIA MAST Trial Clears Intratumoral Combination Cohort 1

September 3, 2023

S&P DJI Announces September 2023 Quarterly Rebalance

September 1, 2023

Preliminary Final Report

August 25, 2023

Imugene completes $35M Placement & Launches c.$30M SPP

August 17, 2023

Imugene Licenses Allogeneic CD19 CAR T Cell Therapy

August 15, 2023

Imugene VAXINIA Trial clears Cohort 3 of IT Monotherapy

August 13, 2023

Imugene CF33 Oncolytic Virus Study to be Showcased at SITC

August 2, 2023

Imugene HER-Vaxx and CHECKVacc to be Featured at ESMO

July 24, 2023

Imugene and RenovoRx CF33 Virotherapy Delivery Collaboration

July 20, 2023

Imugene Oncolytic Virotherapy CF33 Patent Allowed in the US

July 19, 2023

New Dose Escalation in Phase I Clinical Trial of CHECKvacc

July 6, 2023

HER-Vaxx induced antibodies correlated with tumour reduction

June 29, 2023

Imugene PD1-Vaxx patent extended to 2040

June 28, 2023

Imugene Advances VAXINIA MAST Trial to Next IV Cohorts

June 8, 2023

Imugene doses first combination patient in PD1-Vaxx trial

May 31, 2023

Imugene secures IND approval for first-in-class onCARlytics trial

May 19, 2023

FDA clears Imugene IND for onCARlytics first-in-class study

May 18, 2023

onCARlytics with ARTEMIS T cells show anti-tumour activity

May 17, 2023

onCARlytics with Artemis T cells abstract presented at ASGCT

May 2, 2023

Imugene receives $12.6m R&D tax refund

April 25, 2023

Imugene Images and Follows CHECKVacc in TNBC Patients

April 19, 2023

First patients dosed in IT & IV cohort 3 of VAXINIA trial

April 4, 2023

First Patients Dosed in Combination Study of VAXINIA

March 2, 2023

Imugene PD1-Vaxx Immunotherapy Patent Granted in the US

February 9, 2023

Imugene VAXINIA trial advances to Combination Cohort

February 1, 2023

Imugene Receives Vaxinia Ethics Approval in Australia

January 8, 2023

CHECKVacc Data Presented at the 2022 SABC Symposium

December 8, 2022

First Patient Dosed in VAXINIA Intravenous Cohort 2

December 4, 2022

Imugene onCARlytics with Estrella ARTEMIS T Cells SITC

November 13, 2022

Dose escalates In Phase I Clinical Trial of New Oncolytic Vi

November 11, 2022

Imugene onCARlytics with blinatumomab SITC presentation

November 10, 2022

Europe Patent granted for iNKT Cell Therapy Platform

November 6, 2022

First patient dosed in VAXINIA intratumoral cohort 2

October 30, 2022

Preclinical trial of ALA iNKT therapy and IMU onCARlytics

September 26, 2022

First patient IV dosed in VAXINIA Phase 1 clinical trial

September 20, 2022

OGTR grants VAXINIA DIR licence allowing trial expansion

September 19, 2022

Prospectus for the issue of institutional placement options

September 16, 2022

Imugene announces a$80 million institutional placement

September 12, 2022

Imugene doses first patient in nextHERIZON Phase 2 trial

September 7, 2022

Imugene Dose Escalates in Phase I Clinical Trial of VAXINIA

August 31, 2022

Annual Report and Appendix 4E

August 30, 2022

First cohort 3 patient dosed in clinical trial of CHECKvacc

August 9, 2022

Imugene Presents New PD1-Vaxx Data at the 2022 WCLC

August 7, 2022

← Newer news releases · Older news releases →

Decks

The 5 newest of 54 decks. Every deck is listed under its year.